Vernalis plc (LON:VER) insider David Mackney sold 27,233 shares of the firm’s stock in a transaction dated Wednesday, October 12th. The shares were sold at an average price of GBX 39 ($0.48), for a total transaction of £10,620.87 ($13,144.64).
Vernalis plc (LON:VER) opened at 39.5721 on Monday. The stock has a 50 day moving average of GBX 42.26 and a 200 day moving average of GBX 44.77. Vernalis plc has a 52 week low of GBX 31.00 and a 52 week high of GBX 75.00. The company’s market cap is GBX 208.23 million.
VER has been the subject of several research reports. Stifel Nicolaus restated a “buy” rating on shares of Vernalis plc in a research report on Friday, June 24th. Panmure Gordon restated a “buy” rating and issued a GBX 76 ($0.94) price objective on shares of Vernalis plc in a research report on Friday, July 8th. Shore Capital restated a “house stock” rating on shares of Vernalis plc in a research report on Friday, July 8th. Canaccord Genuity restated a “buy” rating and issued a GBX 84 ($1.04) price objective on shares of Vernalis plc in a research report on Friday, July 8th. Finally, N+1 Singer restated a “hold” rating and issued a GBX 46 ($0.57) price objective on shares of Vernalis plc in a research report on Thursday, September 29th. One equities research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. Vernalis plc has a consensus rating of “Buy” and an average target price of GBX 73 ($0.90).
Vernalis plc Company Profile
Vernalis plc is a commercial-stage pharmaceutical holding company. The Company is engaged in the research, development and commercialization of pharmaceutical products for a range of medical disorders. The Company has two marketed products: Tuzistra XR in the United States prescription cough cold market, and frovatriptan, an acute treatment for migraine.
Receive News & Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related companies with MarketBeat.com's FREE daily email newsletter.